• English
  • 简体中文
Login Register
Current Location: Home > Feedback Help Print

【结 构 式】

【分子编号】68928

【品名】2-phenyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline

【CA登记号】 

【 分 子 式 】C21H22BNO2

【 分 子 量 】331.222

【元素组成】C 76.15% H 6.69% Cl 3.26% N 4.23% O 9.66%

与该中间体有关的原料药合成路线共 2 条

合成路线1

该中间体在本合成路线中的序号:(XI)

In one strategy, condensation of amine (I) with 3-methylenecyclobutanecarboxylic acid (II) in the presence of EDC and HOBt in CH2Cl2 yields amide (III), which then undergoes cyclization to the imidazo[1,5-a]pyrazine derivative (IV) upon heating with POCl3 in DMF. Oxidation of alkene (IV) by means of K2OsO4·2H2O in the presence of NMMO in THF/H2O furnishes the 1-(hydroxymethyl)cyclobutanol (V), which is then subjected to chloride displacement with NH3 in i-PrOH to produce the 8-aminoimidazo[1,5-a]pyrazine derivative (VI). Oxidative cleavage of diol (VI) by means of NaIO4 in THF/H2O yields the cyclobutanone (VII), which upon addition of MeLi in THF and subsequent separation of the obtained isomers using TLC affords linsitinib .
In another strategy, condensation of amine (I) with 3-hydroxy-3-methylcyclobutanecarbonyl chloride (VIII) in the presence of DIEA and DMAP in CH2Cl2 produces carboxamide (IX). Cyclization of amide (IX) with POCl3 at 70 °C followed by treatment with NH3 then leads to the imidazo[1,5-a]pyrazine derivative (X). Displacement of the 8-chloroimidazo[1,5-a]pyrazine derivative (X) with NH3 at 110 °C and subsequent chromatographic separation of the isomers provides linsitinib .
In the third strategy, linsitinib is obtained by Suzuki coupling of the quinolinylboronate (XI) with the 1-bromoimidazo[1,5-a]pyrazine derivative (XII) in the presence of PdCl2(dppf)·CH2Cl2 and K2CO3 at 90 °C .

1 Arnold, L.D., Cesario, C., Coate, H. et al. (OSI Pharmaceuticals, Inc.). 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors. EP 1740591, EP 2168968, EP 2305682, EP 2308879, JP 2007531754, JP 2009197013, US 200635031, WO 005097800.
2 Volk, B., Buck, E., Coate, H. et al. OSI-906: A novel, potent, and selective first-in-class small molecule insulin-like growth factor 1 receptor (IGF-1R) inhibitor in phase I clinical trials. 238th ACS Natl Meet (Aug 16-20, Washington) 2009, Abst MEDI 152.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(I) 68918 (3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methanamine   C20H15ClN4 详情 详情
(II) 68919 3-methylenecyclobutanecarboxylic acid;3-Methylenecyclobutylcarboxylic acid 15760-36-8 C6H8O2 详情 详情
(III) 68920 N-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)-3-methylenecyclobutanecarboxamide   C26H21ClN4O 详情 详情
(IV) 68921 7-(8-chloro-3-(3-methylenecyclobutyl)imidazo[1,5-a]pyrazin-1-yl)-2-phenylquinoline    C26H19ClN4 详情 详情
(V) 68922 3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-(hydroxymethyl)cyclobutanol   C26H21ClN4O2 详情 详情
(VI) 68923 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-(hydroxymethyl)cyclobutanol   C26H23N5O2 详情 详情
(VII) 68924 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)cyclobutanone   C25H19N5O 详情 详情
(VIII) 68926 3-hydroxy-3-methylcyclobutanecarbonyl chloride   C6H9ClO2 详情 详情
(IX) 68925 N-((3-chloropyrazin-2-yl)(2-phenylquinolin-7-yl)methyl)-3-hydroxy-3-methylcyclobutanecarboxamide   C26H23ClN4O2 详情 详情
(X) 68927 3-(8-chloro-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol   C26H21ClN4O 详情 详情
(XI) 68928 2-phenyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline   C21H22BNO2 详情 详情
(XII) 68929     C11H13BrN4O 详情 详情

合成路线2

该中间体在本合成路线中的序号:(XI)

In one method, oxidation of 4-chloro-2-nitrotoluene (XXIV) with NaIO4 in the presence of DMFA in DMF at 135 °C yields 4-chloro-2-nitrobenzaldehyde (XXV). Reduction of the nitro group in compound (XXV) with Fe and HCl in EtOH/H2O, followed by Friedländer condensation of the resulting aminoaldehyde with acetophenone (XIV) using KOH at reflux gives 7-chloro-2-phenylquinoline (XXVI). Miyaura borylation of chloroquinoline (XXVI) with bis(pinacolato)diboron (XXVII) in the presence of 1,3-bis(2,6-diisopropylphenyl)imidazolium chloride [IPr·HCl], Pd(OAc)2 and KOAc in refluxing THF furnishes boronate ester (XI).
In another method, arylation of 7-quinolinol (XXVIII) using phenyl lithium in THF, optionally after protection of the hydroxyl group with TBDMSCl in the presence of DMAP and Et3N in CH2Cl2, leads to 2-phenyl-7-quinolinol (XXIX). Quinolinol (XXIX) is then activated by Tf2O in pyr/CH2Cl2 to produce the aryl triflate (XXX), which condenses with bis(pinacolato)diboron (XXVII) in the presence of PdCl2(dppf) CH2Cl2, dppf and KOAc in 1,4-dioxane to afford the dioxaborolane derivative (XI) .

1 Arnold, L.D., Cesario, C., Coate, H. et al. (OSI Pharmaceuticals, Inc.). 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors. EP 1740591, EP 2168968, EP 2305682, EP 2308879, JP 2007531754, JP 2009197013, US 200635031, WO 005097800.
中间体序号 中间体编号 品名 CAS号 分子式 供应商 用于合成
(XI) 68928 2-phenyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)quinoline   C21H22BNO2 详情 详情
(XIV) 10317 Acetophenone 98-86-2 C8H8O 详情 详情
(XXIV) 41485 4-chloro-1-methyl-2-nitrobenzene;4-chloro-2-nitrotoluene;4-chloro-1-methyl-2-nitro-benzene 89-59-8 C7H6ClNO2 详情 详情
(XXV) 68938 4-chloro-2-nitrobenzaldehyde;2-Nitro-4-chlorobenzaldehyde 5551-11-1 C7H4ClNO3 详情 详情
(XXVI) 68939 7-chloro-2-phenylquinoline   C15H10ClN 详情 详情
(XXVII) 53342 4,4,4',4',5,5,5',5'-Octamethyl-2,2'-bi-1,3,2-dioxaborolane; Bis(pinacolato)diboron; Diboron pinacol ester 73183-34-3 C12H24B2O4 详情 详情
(XXVIII) 68940 quinolin-7-ol   C9H7NO 详情 详情
(XXIX) 68941 2-phenyl-7-quinolinol;2-phenylquinolin-7-ol   C15H11NO 详情 详情
(XXX) 68942 2-phenylquinolin-7-yl trifluoromethanesulfonate   C16H10F3NO3S 详情 详情
Extended Information